1. Home
  2. FEIM vs BOLD Comparison

FEIM vs BOLD Comparison

Compare FEIM & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frequency Electronics Inc.

FEIM

Frequency Electronics Inc.

HOLD

Current Price

$60.41

Market Cap

722.9M

Sector

Industrials

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$2.88

Market Cap

60.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEIM
BOLD
Founded
1961
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
722.9M
60.8M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
FEIM
BOLD
Price
$60.41
$2.88
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$51.50
$4.00
AVG Volume (30 Days)
197.7K
186.8K
Earning Date
03-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$63,227,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$21.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.05
$0.96
52 Week High
$80.60
$3.16

Technical Indicators

Market Signals
Indicator
FEIM
BOLD
Relative Strength Index (RSI) 41.66 58.72
Support Level $55.50 $2.71
Resistance Level $79.30 $2.97
Average True Range (ATR) 3.72 0.13
MACD -1.02 -0.02
Stochastic Oscillator 13.37 33.88

Price Performance

Historical Comparison
FEIM
BOLD

About FEIM Frequency Electronics Inc.

Frequency Electronics Inc is a world leader in precision time and frequency generation technology, which is incorporated into commercial and U.S. Government satellites, Command, Control, Communication, Computer, Intelligence, Surveillance and Reconnaissance, and Electronic Warfare systems. Its technology is used for a wide range of space and non-space applications. The company has two segments FEI-NY, and FEI-Zyfer. Majority of revenue come from FEI-NY which provides precision time, frequency generation and synchronization products and subsystems that are found on-board satellites, in ground-based communication systems and imbedded in mobile platforms operated by the U.S. military.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: